248 related articles for article (PubMed ID: 16844149)
1. The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
Kuzhikandathil EV; Bartoszyk GD
Neuropharmacology; 2006 Sep; 51(4):873-84. PubMed ID: 16844149
[TBL] [Abstract][Full Text] [Related]
2. Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines.
Kuzhikandathil EV; Yu W; Oxford GS
Mol Cell Neurosci; 1998 Dec; 12(6):390-402. PubMed ID: 9888991
[TBL] [Abstract][Full Text] [Related]
3. D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins.
Liu LX; Burgess LH; Gonzalez AM; Sibley DR; Chiodo LA
Synapse; 1999 Feb; 31(2):108-18. PubMed ID: 10024007
[TBL] [Abstract][Full Text] [Related]
4. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
[TBL] [Abstract][Full Text] [Related]
5. D2-like dopamine receptors modulate SKCa channel function in subthalamic nucleus neurons through inhibition of Cav2.2 channels.
Ramanathan S; Tkatch T; Atherton JF; Wilson CJ; Bevan MD
J Neurophysiol; 2008 Feb; 99(2):442-59. PubMed ID: 18094105
[TBL] [Abstract][Full Text] [Related]
6. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
Oz M; Zhang L; Rotondo A; Sun H; Morales M
Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
[TBL] [Abstract][Full Text] [Related]
7. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
[TBL] [Abstract][Full Text] [Related]
8. Voltage-dependence of the human dopamine D2 receptor.
Sahlholm K; Nilsson J; Marcellino D; Fuxe K; Arhem P
Synapse; 2008 Jun; 62(6):476-80. PubMed ID: 18361445
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical regulation of dopamine receptors in transfected 293 cells.
Filtz TM; Artymyshyn RP; Guan W; Molinoff PB
Mol Pharmacol; 1993 Aug; 44(2):371-9. PubMed ID: 8102783
[TBL] [Abstract][Full Text] [Related]
10. Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells.
Boundy VA; Pacheco MA; Guan W; Molinoff PB
Mol Pharmacol; 1995 Nov; 48(5):956-64. PubMed ID: 7476927
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus.
Floran B; Floran L; Erlij D; Aceves J
Eur J Pharmacol; 2004 Sep; 498(1-3):97-102. PubMed ID: 15363981
[TBL] [Abstract][Full Text] [Related]
12. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
[TBL] [Abstract][Full Text] [Related]
13. The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells.
Zhang LJ; Lachowicz JE; Sibley DR
Mol Pharmacol; 1994 May; 45(5):878-89. PubMed ID: 7910658
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
15. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
Schetz JA; Chu A; Sibley DR
J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals.
Wilke RA; Hsu SF; Jackson MB
J Pharmacol Exp Ther; 1998 Feb; 284(2):542-8. PubMed ID: 9454795
[TBL] [Abstract][Full Text] [Related]
17. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
19. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition.
Huang R; Griffin SA; Taylor M; Vangveravong S; Mach RH; Dillon GH; Luedtke RR
Pharmacology; 2013; 92(1-2):84-9. PubMed ID: 23942137
[TBL] [Abstract][Full Text] [Related]
20. D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent.
Beazely MA; Tong A; Wei WL; Van Tol H; Sidhu B; MacDonald JF
J Neurochem; 2006 Sep; 98(5):1657-63. PubMed ID: 16879713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
